Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
atopic dermatitis
Biotech
Bausch + Lomb and Celldex rocked by respective ph. 2 flops
While Celldex ended work in the indication in response to the setback, Bausch + Lomb made the case for talks about entering phase 3.
Nick Paul Taylor
Nov 20, 2026 5:20am
Aclaris drops TSLP program after failing ph. 2 eczema test
Nov 16, 2026 8:20am
AbCellera becomes latest biotech to abandon OX40 drug
Nov 10, 2026 5:06am
Parkinson’s-focused Aspen and bispecifics Bambusa plan IPOs
Oct 12, 2026 2:00am
Enveda reaps $311M round to help become ‘household name’
Sep 23, 2026 9:47am
Retension, Lilly-backed TRex both plan to join IPO stampede
Sep 21, 2026 4:29am